26.14
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Analyzing drawdowns of Travere Therapeutics Inc. with statistical toolsJuly 2025 Sentiment & Risk Controlled Stock Pick Alerts - newser.com
How moving averages guide Travere Therapeutics Inc. tradingCEO Change & Free High Return Stock Watch Alerts - newser.com
Is Travere Therapeutics Inc. stock supported by strong fundamentals2025 Earnings Surprises & Safe Swing Trade Setup Alerts - newser.com
Why Travere Therapeutics Inc. stock could outperform in 2025Market Volume Summary & Real-Time Buy Zone Alerts - newser.com
Will Travere Therapeutics Inc. stock deliver consistent dividendsJuly 2025 Weekly Recap & Reliable Intraday Trade Plans - newser.com
Can Travere Therapeutics Inc. stock outperform in 2025 bull marketMarket Activity Summary & Breakout Confirmation Trade Signals - newser.com
Backtesting results for Travere Therapeutics Inc. trading strategiesJuly 2025 Patterns & Consistent Profit Alerts - newser.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 10, 2025 - BioSpace
Will Travere Therapeutics Inc. price bounce be sustainableQuarterly Investment Review & Fast Moving Trade Plans - newser.com
What moving averages say about Travere Therapeutics Inc.Quarterly Investment Review & Stepwise Entry/Exit Trade Alerts - newser.com
Travere Therapeutics (NASDAQ:TVTX) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Travere rises as FDA says no AdCom required for Filspari label expansion - MSN
Focal Segmental Glomerulosclerosis Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Retrophin, AbbVie, AstraZeneca, Pfizer, Sanofi, Teva Pharma - The Globe and Mail
How to recover losses in Travere Therapeutics Inc. stock2025 Technical Patterns & Safe Capital Growth Trade Ideas - newser.com
Can Travere Therapeutics Sustain Its 48.9% Rally Amid Pipeline Progress in 2025? - Yahoo Finance
Travere Therapeutics, Inc. (TVTX) Stock Analysis: A Biotech Star with 37.50% Upside Potential - DirectorsTalk Interviews
Can trapped investors hope for a rebound in Travere Therapeutics Inc.Market Performance Report & Technical Pattern Recognition Alerts - newser.com
What dividend safety score for Travere Therapeutics Inc. stockQuarterly Trade Summary & Free Verified High Yield Trade Plans - newser.com
What candlestick patterns are forming on Travere Therapeutics Inc.Market Activity Summary & Breakout Confirmation Alerts - newser.com
Real time breakdown of Travere Therapeutics Inc. stock performanceJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
Travere therapeutics CFO sells $104,463 in stock - MSN
Building trade automation scripts for Travere Therapeutics Inc.Bond Market & Real-Time Market Sentiment Alerts - newser.com
Heatmap analysis for Travere Therapeutics Inc. and competitors2025 Volatility Report & Fast Entry and Exit Trade Plans - newser.com
Why Travere Therapeutics Inc. (TVTX) Went Up On Tuesday? - MSN
Published on: 2025-10-03 01:41:47 - newser.com
Why Travere Therapeutics Inc. stock remains on watchlists2025 Buyback Activity & Verified Short-Term Trading Plans - newser.com
Using data tools to time your Travere Therapeutics Inc. exit2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Travere Therapeutics stock rises on sNDA submission plans for FILSPARI - MSN
How to use a screener to detect Travere Therapeutics Inc. breakoutsGap Up & Risk Controlled Stock Alerts - newser.com
Travere Therapeutics (NASDAQ:TVTX) Trading Down 7.6%What's Next? - MarketBeat
Travere therapeutics CAO Calvin Sandra sells $17,520 in stock - MSN
Published on: 2025-09-29 13:53:58 - newser.com
Published on: 2025-09-29 12:50:11 - newser.com
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):